- p16INK4a immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotyping
-
Nishio S, Fujii T, Nishio H, Kameyama K, Saito M, Iwata T, Kubushiro , Aoki D
- KMID: 2288527
- J Gynecol Oncol.
- 2013 Jul;24(3):215-221.
- doi: 10.3802/jgo.2013.24.3.215
OBJECTIVE: In cervical intraepithelial neoplasia (CIN), p16INK4a immunohistochemistry has been reported to be a useful diagnostic biomarker. However, limited information is available about the association between the p16INK4a immunohistochemistry and... -
- CITED
-
- Close
- SHARE
-
- Close
- Controversies surrounding type III radical abdominal hysterectomy and its procedure using new instruments
-
Ushijima K, Takemoto S, Kawano K, Nishio S, Terada A, Tsuda N, Sonoda G, Ota SI, Kamura T
- KMID: 1992617
- Korean J Obstet Gynecol.
- 2012 Apr;55(4):225-229.
- doi: 10.5468/KJOG.2012.55.4.225
Type III radical abdominal hysterectomy (RAH) is standard care for early stage cervical cancer. For the past few decades, there has been a remarkable shift from surgery to radiation, in... -
- CITED
-
- Close
- SHARE
-
- Close
- Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing device
-
Tsuda N, Ushijima K, Kawano K, Takemoto S, Nishio S, Sonoda G, Kamura T
- KMID: 2130104
- J Gynecol Oncol.
- 2014 Jul;25(3):229-235.
- doi: 10.3802/jgo.2014.25.3.229
OBJECTIVE: A number of new techniques have been developed to prevent lymphocele formation after pelvic lymphadenectomy in gynecologic cancers. We assessed whether the electrothermal bipolar vessel sealing device (EBVSD) could... -
- CITED
-
- Close
- SHARE
-
- Close
- Epithelial borderline ovarian tumor: Diagnosis and treatment strategy
-
Ushijima K, Kawano K, Tsuda N, Nishio S, Terada A, Kato H, Tasaki K, Matsukuma
- KMID: 2148929
- Obstet Gynecol Sci.
- 2015 May;58(3):183-187.
- doi: 10.5468/ogs.2015.58.3.183
Epithelial borderline ovarian tumors (BOT) are distinctive from benign tumors and carcinoma. They occur in younger women more often than carcinoma, and there is some difficulty making correct diagnosis of... -
- CITED
-
- Close
- SHARE
-
- Close
- Identification of appropriate cone length to avoid positive cone margin in high grade cervical intraepithelial neoplasia
-
Kawano K, Tsuda N, Nishio S, Yonemoto K, Tasaki K, Tasaki R, Ushijima K
- KMID: 2374255
- J Gynecol Oncol.
- 2016 Sep;27(5):e54.
- doi: 10.3802/jgo.2016.27.e54
OBJECTIVE: To identify key factors for predicting positive cone margin and appropriate cone length. METHODS: We retrospectively reviewed the margin status of patients who received conization with high grade cervical intraepithelial... -
- CITED
-
- Close
- SHARE
-
- Close
- A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial
-
Hori K, Nishio S, Ushijima K, Kasamatsu Y, Kondo E, Takehara K, Ito K
- KMID: 2526119
- J Gynecol Oncol.
- 2021 Jul;32(4):e64.
- doi: 10.3802/jgo.2021.32.e64
Objective To determine the safety and efficacy of dose-dense (dd) paclitaxel (PTX) and carboplatin (CBDCA) in treating advanced or recurrent endometrial cancer. Methods Women aged 20–75 years with histologically confirmed endometrial cancer, the... -
- CITED
-
- Close
- SHARE
-
- Close
- Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
-
Ushijima K, Fujiyoshi , Kawano K, Tsuda N, Nishio S, Eto H, Kamura T
- KMID: 2288540
- J Gynecol Oncol.
- 2013 Apr;24(2):108-113.
- doi: 10.3802/jgo.2013.24.2.108
OBJECTIVE: To evaluate the clinical efficacy of concurrent chemoradiotherapy (CCRT) using daily low-dose cisplatin for cervical cancer. METHODS: Fifty-one patients with locally advanced cervical cancer (FIGO stage IB2, bulky IIA, IIB-IVA)... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
-
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Keiichi K, Kondo E, Sugiyama T, Tabata T
- KMID: 2526299
- J Gynecol Oncol.
- 2021 Jan;32(1):e9.
- doi: 10.3802/jgo.2021.32.e9
Objective: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131)
-
Nishio S, Aihara S, Shimokawa , Fujishita , Taniguchi , Hachisuga , Yanazume S, Kobayashi , Murakami F, Numa F, Kotera K, Okura N, Toki N, Yokoyama M, Ushijima K
- KMID: 2417468
- J Gynecol Oncol.
- 2018 Sep;29(5):e77.
- doi: 10.3802/jgo.2018.29.e77
OBJECTIVE: Palonosetron is effective for the management of acute and delayed chemotherapy-induced nausea and vomiting (CINV). While emetogenic carboplatin-based chemotherapy is widely used to treat gynecologic cancers, few studies have... -
- CITED
-
- Close
- SHARE
-
- Close
